 MaxCyte Inc AIM:MXCT has seen its shares grow after a US deal. The company, which specialises in technology for ex-vivo cell engineering, has signed a licence agreement with Intima Bioscience, which is developing genetically engineered cell therapies for solid tumor cancer. 